BETA

IPO registrations (S-1, F-1) · Registrants

PTC THERAPEUTICS, INC.

SEC CIK
1070081 · filings on EDGAR ↗
Former names
PTC THERAPEUTICS INC (2004–2005)
Registration
Form S-1, first filed 2006-03-31, last 2014-02-12; 3 initial registrations, 7 amendments
Outcome
Final prospectus filed 2013-06-20; declared effective 2013-06-19; withdrawal requested 2007-04-20
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
500 WARREN CORPORATE CENTER DRIVE, Warren, NJ 07059
EIN
04-3416587
Ticker
PTCT (Nasdaq)
EDGAR entity type
operating
Insiders and CEO pay
PTC THERAPEUTICS, INC. on the corporate pages

Offering terms

Proposed price range
$13.00–$16.00 per share (S-1/A filed 2013-06-13)
Final price
$15.00 per share, within the range (424B4 filed 2013-06-20, an initial public offering)
Shares sold
8,372,000
Gross proceeds
$125,580,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol PTCT
Lead underwriters
J.P. Morgan (3,516,240 shares)
Syndicate
Credit Suisse (2,762,760); Cowen (1,465,100); Wedbush Securities (627,900)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 17

FiledFormWhat it isName as filedEDGAR
2006-03-31S-1S-1 (registration)PTC THERAPEUTICS, INC.0000950123-06-004032 ↗
2006-05-04S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0000950123-06-005689 ↗
2006-05-19S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0000950123-06-006711 ↗
2007-04-20RWRW (withdrawal request)PTC THERAPEUTICS, INC.0000950123-07-005687 ↗
2013-05-16S-1S-1 (registration)PTC THERAPEUTICS, INC.0001047469-13-006241 ↗
2013-05-28S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0001047469-13-006525 ↗
2013-06-05S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0001047469-13-006735 ↗
2013-06-13S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0001047469-13-006950 ↗
2013-06-19S-1MEFS-1MEF (added securities)PTC THERAPEUTICS, INC.0001104659-13-050214 ↗
2013-06-19EFFECTEFFECT (declared effective)PTC THERAPEUTICS, INC.9999999995-13-001852 ↗
2013-06-20424B4424B4 (final prospectus)PTC THERAPEUTICS, INC.0001047469-13-007101 ↗
2014-01-31S-1S-1 (registration)PTC THERAPEUTICS, INC.0001047469-14-000473 ↗
2014-02-10S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0001047469-14-000743 ↗
2014-02-12S-1/AS-1/A (amendment)PTC THERAPEUTICS, INC.0001047469-14-000824 ↗
2014-02-12S-1MEFS-1MEF (added securities)PTC THERAPEUTICS, INC.0001104659-14-009209 ↗
2014-02-12EFFECTEFFECT (declared effective)PTC THERAPEUTICS, INC.9999999995-14-000434 ↗
2014-02-14424B4424B4 (final prospectus)PTC THERAPEUTICS, INC.0001047469-14-000884 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2013-06-13S-1/Aregistration statement$13.00–$16.00$20.266,900,000$139,794,000Nasdaq PTCT4primary document; range, price line, shares headline, proceeds computed, cover names 4document ↗
2013-06-20424B4final prospectus$15.008,372,000$125,580,000Nasdaq PTCT4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
ALDRICH RICHARDDirector62013–2015
Almstead Neil GregoryOfficerChief Technical Ops Officer; CHIEF TECHNICAL OPS OFFICER; EVP, Research and CMC; EVP Research Pharma Ops & Tech; Senior VP, Research and CMC602013–2026
Barth Jay AllanOfficerVP, Clinical Development12013
Bolte AxelDirector22013
Boulding Mark ElliottOfficerExec VP and CLO; Exec. VP and CLO; Exec. VP, and CLO; EXEC. VP AND CLO572013–2026
CREDIT SUISSE AG/Other; TenPercentOwner22013
Hirawat Claudia de Oliveira RibeiroOfficerPresident102013–2015
Jacobson Allan StevenDirector272013–2026
Koppel AdamDirector72013–2017
Kovacs Shane William CharlesOfficerChief Financial Officer; EVP, CFO & Head of Corp Dev92013–2017
Kranda Michael LDirector52013–2015
McDonough Cameron GeoffreyDirector52013–2017
Peltz Stuart WalterDirector,OfficerChief Executive Officer; CHIEF EXECUTIVE OFFICER482013–2023
Rothera MarkOfficerChief Commercial Officer262013–2017
SCHMERTZLER MICHAELDirector; Director,TenPercentOwner302013–2026
SOUTHWELL DAVID PDirector232013–2026person page Fuzzy
ZELDIS JEROME BDirector162013–2026
ALLEN PAUL GDirector22013
Cougar Investment Holdings LLCDirector22013
VCVC III LLCDirector22013
VCVC Management III LLCDirector22013
Vulcan Capital Venture Capital I LLCDirector22013
Vulcan Capital Venture Capital Management I, LLCDirector22013
Vulcan Ventures Inc.Director22013
HBM Healthcare Investments (Cayman) Ltd.TenPercentOwner32013
Spiegel Robert J.OfficerChief Medical Officer62014–2016
Renaud Ronald C JRDirector52014–2017
STEELE GLENN JR MD PHDDirector132015–2026
Ong TuyenOfficerChief Medical Officer22016–2017
Svoronos DawnDirector132016–2022
Complete Pharma Holdings II, LLCTenPercentOwner22017
Souza MarcioOfficerChief Operating Officer122017–2020
Utter Christine MarieOfficerPrincipal Financial Officer; SVP, CHIEF ACCOUNTING OFFICER; SVP, Finance & CAO; SVP, FINANCE & CAO422017–2026
Okey StephanieDirector172018–2026
Reeve EmmaDirector192018–2026
Hill Emily LuisaOfficerChief Financial Officer; CHIEF FINANCIAL OFFICER222019–2023
Klein Matthew B.Director,Officer; OfficerChief Development Officer; CHIEF EXECUTIVE OFFICER; Chief Operating Officer; CHIEF OPERATING OFFICER342020–2026
Pauwels EricDirector,Officer; OfficerChief Business Officer; CHIEF BUSINESS OFFICER; CHIEF EXECUTIVE OFFICER372020–2026
Smith Mary L.Director82021–2026
Young AlethiaDirector72022–2026
Bell William F. Jr.Director32023–2024
Golden Lee ScottOfficerChief Medical Officer; CHIEF MEDICAL OFFICER; EVP & CHIEF MEDICAL OFFICER152023–2026
Gravier PierreOfficerCHIEF FINANCIAL OFFICER122023–2026
Chutter Jessica CarolineDirector22026
Sollie-Zetlmayer Hege ElisabethDirector22026

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2023-05-08PTC THERAPEUTICS, INC.Biotechnology$35,897,425$35,897,425401
2020-06-12PTC THERAPEUTICS, INC.Biotechnology$41,905,000$41,905,000381
2020-05-14PTC THERAPEUTICS, INC.Biotechnology$140,949,151$140,949,151571
2018-09-05PTC THERAPEUTICS, INC.Biotechnology$150,000,000$150,000,000521

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationPTC Therapeutics, Inc.NJState business registriesname and state
Business registrationPTC Therapeutics, Inc.NJState business registriesname and state
Business registrationPTC Therapeutics, Inc.NJState business registriesname and state
Business registrationPTC Therapeutics, Inc.NJState business registriesname and state
Business registrationPTC THERAPEUTICS, INC.NJState business registriesEIN (EXACT, as the state registration reports it)
Business registrationPTC THERAPEUTICS, INC.NJState business registriesname and state
Business registrationPTC THERAPEUTICS, INC.NJState business registriesname and state
Business registrationPTC THERAPEUTICS, INC.NJState business registriesname and state
Federal award recipientPTC THERAPEUTICS, INC.NJFederal spending (USAspending)name and state
Form D issuerPTC THERAPEUTICS, INC.NJForm D private offeringsCIK (EXACT)
Lobbying clientPTC THERAPEUTICSNJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICSNJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICSNJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICS INC.NJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICS INC.NJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICS, INC.NJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICS, INC.NJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICS, INC.NJFederal lobbying (LDA)name and state
Lobbying clientPTC THERAPEUTICS, INC.NJFederal lobbying (LDA)name and state
Lobbying registrantPTC THERAPEUTICS, INC.NJFederal lobbying (LDA)name and state
Paying companyPTC Therapeutics, Inc.NJOpen Payments (drug and device company payments)name and state
Patent assigneePTC THERAPEUTICS, INC.NJPatents (USPTO)name and state
SEC filerPTC THERAPEUTICS, INC.SEC filers (EDGAR)CIK (EXACT)
Trademark ownerPTC Therapeutics, Inc.NJTrademarks (USPTO)name and state
Form 5500 plan sponsorPTC THERAPEUTICS, INC.EIN (EXACT)
Person pageDavid P SouthwellPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Pharmaceutical Preparations, NJ first:

More with this interest.

In other datasets, the same topic (Health) in NJ:

Interests: Pharmaceutical Preparations · Health